The U.S. Food and Drug Administration’s (FDA) ambitious drive towards "radical transparency," particularly through the public release of Complete Response Letters (CRLs), is facing scrutiny from former agency officials. While intended to demystify the drug approval process, this heightened openness, they argue, may be inadvertently blurring the lines of official policy and creating a new layer of uncertainty for pharmaceutical developers. This concern was a central theme at a panel discussion held during the 2026 BIO International Convention in San Diego, from June 22-25.
The Genesis of "Radical Transparency"
The push for greater openness at the FDA gained significant momentum in July 2025, under the tenure of then-Commissioner Dr. Marty Makary. At that time, the agency announced its intention to make CRLs, the official documents detailing why a drug application has not been approved, publicly accessible. The stated objective was to eliminate "a guessing game when navigating the FDA," providing developers with clearer insights into the agency’s decision-making process and the specific hurdles that drug candidates face. This move was lauded by many within the industry as a positive step towards a more predictable regulatory environment.
Prior to this initiative, the content and accessibility of CRLs were largely confidential, often leading to speculation and frustration among drug manufacturers who struggled to decipher the precise reasons for rejection. The aim was to replace this opacity with a more direct and informative exchange.
Emerging Concerns: Transparency Versus Clarity
However, the panel of former FDA employees at the BIO International Convention presented a nuanced perspective, suggesting that the very mechanisms designed to enhance transparency might be compromising the clarity of official policy. The core of their argument centers on the perceived relaxation of standards for agency announcements and the interpretation of information disseminated under the banner of increased openness.
Joe Franklin, BIO’s chief legal and policy advisor and a former senior advisor to the FDA Commissioner, highlighted that calls for more detailed CRLs have existed for years. He acknowledged that the current administration has undertaken more significant actions in this regard than previous ones. Yet, he cautioned that "there are limits to what can be done." Franklin elaborated that while the intention to provide more information is commendable, the practical implementation can lead to unintended consequences.
The Practical Challenges of Disclosure
Elizabeth Jungman, former FDA chief of staff and now a partner at Hogan Lovells, pointed to the practical constraints that can hinder effective transparency. She noted that in certain instances, legal restrictions prevent the public disclosure of specific information within CRLs. Furthermore, she raised concerns about the impact of recent "mass redundancies" within the FDA workforce. This reduction in staff, Jungman argued, makes it increasingly impractical for the agency to engage in the lengthy and resource-intensive negotiations with companies over the redaction of sensitive information. The sheer volume of data that could potentially be included in CRLs, coupled with limited personnel, creates a bottleneck.
Hilary Marston, principal at Canal Row Advisors and formerly chief medical officer at the FDA, echoed these sentiments. She explained that even when CRLs are extensive, an overabundance of cited concerns can paradoxically lead to confusion. When a document lists numerous issues, it becomes difficult for drug developers to discern which concerns are truly critical to the agency’s decision to reject a filing. This can result in developers prioritizing less significant issues while neglecting the core reasons for non-approval, thereby delaying progress and potentially leading to repeated rejections.
Beyond CRLs: The Ambiguity of Alternative Communication Channels
The FDA’s commitment to transparency has extended beyond just CRLs. In an effort to broadly improve communication, official policies have, at times, been announced through less conventional channels, such as articles co-authored by Dr. Marty Makary and Dr. Vinay Prasad, a former head of the Center for Biologics Regulation and Evaluation (CBER). One notable instance involved guidance restricting COVID-19 vaccine boosters, which was communicated through such a medium.
This practice has raised questions about the authoritative weight of these announcements. Ritu Nalubola, former FDA Europe director and now director of life sciences and healthtech at the Marwood Group, expressed concern that with Dr. Prasad no longer in his former role, it is unclear whether these types of announcements represent his personal opinions or reflect official FDA policy. This ambiguity can lead to a significant disconnect for stakeholders who are trying to adhere to the agency’s directives.
A Return to Stricter Standards?
Jungman and Marston recalled a past era when the requirements for FDA press releases and official pronouncements were considerably more stringent. They remember a time when the bar for what constituted an official communication was higher, ensuring a greater degree of certainty for the regulated industry. Under the current, more relaxed standards, they, along with Nalubola, concurred that drug developers are finding it increasingly challenging to ascertain what constitutes "true" FDA policy.
The consensus among these former officials was that the current approach, while well-intentioned, has inadvertently made the regulatory landscape more opaque in practice. The sheer volume of information and the diverse channels through which it is disseminated can overwhelm developers, making it difficult to prioritize and act upon the most critical directives.
Navigating the New Landscape: Advice for Developers
In light of these challenges, the former FDA officials offered practical advice to drug development companies. Their recommendation is to exercise caution and resist the urge to react decisively to every announcement or piece of information released on a day-to-day basis. Instead, they advocate for a more measured approach, urging companies to prioritize and operate primarily based on the fundamental, officially codified FDA guidelines. This means focusing on established regulations, formal guidance documents, and clearly delineated policy statements, rather than interpreting every informal announcement or published article as definitive policy.
This strategic approach aims to insulate developers from the potential confusion arising from less formal or ambiguously attributed communications, allowing them to maintain a focus on core regulatory requirements.
Broader Implications for the Pharmaceutical Industry
The debate surrounding the FDA’s transparency initiatives has far-reaching implications for the pharmaceutical industry. The industry relies heavily on predictable and clear regulatory frameworks to guide its extensive research and development efforts. When the clarity of these frameworks is compromised, it can lead to:
- Increased Development Costs: Uncertainty can lead to misallocated resources, duplicated efforts, and longer development timelines, all of which contribute to higher costs.
- Delayed Market Access: If developers misinterpret policy or focus on less critical issues due to confusion, it can delay the submission and approval of potentially life-saving therapies.
- Erosion of Trust: While transparency is meant to build trust, a lack of clarity can have the opposite effect, leading to frustration and a potential decline in confidence in the regulatory process.
- Impact on Innovation: A complex and confusing regulatory environment can stifle innovation, as companies may be hesitant to invest in novel approaches if they are unsure of the regulatory pathway.
The FDA’s commitment to transparency is a critical component of its mission to protect public health. However, as the discussions at the BIO International Convention highlighted, the agency faces the ongoing challenge of balancing openness with the imperative of clear, actionable policy guidance. The path forward likely involves refining the communication strategies and ensuring that the mechanisms of transparency do not inadvertently obscure the very clarity they aim to achieve. The agency will need to consider how to effectively communicate its policies, ensuring that both the intent and the practical application are understood by all stakeholders, thereby fostering a regulatory environment that is both open and unambiguous. This ongoing dialogue is essential for ensuring the efficient and effective development of safe and effective medical products.
